Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil

18 Jul 2022

Abstract excerpt

To date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine effectiveness (VE) of CoronaVac plus BNT162b2 booster during the period of dominance of the Omicron variant in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Vaccine Coverage and Hesitancy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35851597
DOI: 10.1038/s41467-022-31839-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in BrazilPMID 35851597Read ↗

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in BrazilSemantic proximity Read ↗

Protection conferred by vaccine plus previous infection (hybrid immunity) with vaccines of three different platforms during the Omicron variant period in BrazilSemantic proximity Read ↗

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read ↗

Vaccine effectiveness of CoronaVac against symptomatic and severe COVID-19 among children in Brazil during the Omicron periodSemantic proximity Read ↗

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 Vaccines Against Hospitalisations Among Children and Adolescents During the Omicron Outbreak in ArgentinaSemantic proximity Read ↗

Expert Review of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness & Safety During the Omicron-dominant Phase of the PandemicSemantic proximity Read ↗

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in ArgentinaSemantic proximity Read ↗

Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and ScotlandSemantic proximity Read ↗

Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical TrialSemantic proximity Read ↗

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity Read ↗

Retrospective cohort study of COVID-19 in patients of the Brazilian public health system with SARS-COV-2 Omicron variant infectionSemantic proximity Read ↗

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.